靶向肿瘤微环境:前列腺癌的新治疗途径
本综述检索PubMed截至2023年12月10日的相关研究,阐述肿瘤相关巨噬细胞(TAMs)、癌相关成纤维细胞(CAFs)和髓源性抑制细胞(MDSCs)与前列腺癌细胞在肿瘤微环境中的相互作用机制。这些细胞在前列腺癌发生、进展和转移中起关键作用,并介导对抗雄激素治疗、化疗和免疫治疗的耐药;靶向这些细胞的治疗在临床前模型和若干临床试验中显示有前景的效果,但缺乏可靠的患者选择生物标志物及对其相互作用机制理解不完整,阻碍了临床转化。
要点
- TAMs、CAFs和MDSCs在前列腺癌发生、进展和转移中起关键作用。
- 这些细胞介导对雄激素治疗、化疗和免疫治疗的耐药。
- 靶向这些细胞的治疗在临床前模型和若干临床试验中显示有前景的效果。
核心结论
- 靶向前列腺癌中TAMs、CAFs和MDSCs的新治疗策略具有前景。
- 未来研究应更全面探索这些细胞促进前列腺癌的具体机制,以确定更多药物靶点并开展更多临床试验验证这些治疗策略的安全性和有效性。
研究设计与样本
- 综述:检索PubMed截至2023年12月10日发表的关于前列腺癌中TAMs、CAFs和MDSCs的相关研究。
主要发现
- TAMs、CAFs和MDSCs在前列腺癌的肿瘤发生、进展和转移中起关键作用。
- TAMs、CAFs和MDSCs在很大程度上介导对常规治疗(包括抗雄激素治疗、化疗和免疫治疗)的耐药。
- 靶向这些细胞成分的治疗干预在临床前模型和若干前列腺癌临床试验中,单用或与其他抗癌治疗联合时显示出有前景的效果。
- 缺乏可靠的患者选择生物标志物以及对这类细胞成分与前列腺癌细胞相互作用机制的理解不完整,阻碍了其临床转化和应用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缺乏可靠的患者选择生物标志物。
- 对这些细胞成分与前列腺癌细胞之间相互作用的机制理解不完整,阻碍了其临床转化和应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A growing number of studies have shown that in addition to adaptive immune cells such as CD8 + T cells and CD4 + T cells, various other cellular components within prostate cancer (PCa) tumor microenvironment (TME), mainly tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs) and myeloid-derived suppressor cells (MDSCs), have been increasingly recognized as important modulators of tumor progression and promising therapeutic targets. OBJECTIVE: In this review, we aim to delineate the mechanisms by which TAMs, CAFs and MDSCs interact with PCa cells in the TME, summarize the therapeutic advancements targeting these cells and discuss potential new therapeutic avenues. METHODS: We searched PubMed for relevant studies published through December 10 2023 on TAMs, CAFs and MDSCs in PCa. RESULTS: TAMs, CAFs and MDSCs play a critical role in the tumorigenesis, progression, and metastasis of PCa. Moreover, they substantially mediate therapeutic resistance against conventional treatments including anti-androgen therapy, chemotherapy, and immunotherapy. Therapeutic interventions targeting these cellular components have demonstrated promising effects in preclinical models and several clinical trials for PCa, when administrated alone, or combined with other anti-cancer therapies. However, the lack of reliable biomarkers for patient selection and incomplete understanding of the mechanisms underlying the interactions between these cellular components and PCa cells hinder their clinical translation and utility. CONCLUSION: New therapeutic strategies targeting TAMs, CAFs, and MDSCs in PCa hold promising prospects. Future research endeavors should focus on a more comprehensive exploration of the specific mechanisms by which these cells contribute to PCa, aiming to identify additional drug targets and conduct more clinical trials to validate the safety and efficacy of these treatment strategies.
引用
- Fang B, Lu Y, Li X, et al. Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer. Prostate Cancer Prostatic Dis. 2024. PMID: 38565910. doi:10.1038/s41391-024-00825-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。